

101 Lucas Valley Road, Suite 210 • San Rafael, California 94903 Tel: (415) 479-8628 • Fax: (415) 479-8608 • e-mail: ppsi@aol.com

3939 99 JUN 17 P3:28

May 25, 1999

Janet Woodcock, M.D.
Director, Center for Drug Evaluation
and Research
Department of Health & Human Services
FDA Administration
Washington, D.C. 20857

RE: Docket No. 98P -0169/CP1

Dear Dr. Woodcock:

This is a follow-up to your September 18, 1998 letter regarding PPSI's Citizen Petition requesting the FDA instituting standards for the labeling of botanicals, homeopathics, nutritionals, and natural products which would be similar to the labeling requirements for over-the-counter (OTC) drugs.

Enclosed for your review and comments and to be made part of Docket No. 98P -0169/CP1 are the following:

- 1. Information on Saw Palmetto (five papers)
- a. Jama, November 11, 1998, "Saw Palmetto Extracts for Treatment of Benign Prostatic Hyperplasia A Systematic Review"
 - b. "Efficacy of a Combined Sabal-Urtica Preparation in the Treatment of Benign Prostatic Hyperplasia (BPH)" by Metzker, Kieser & Holscher
 - c. Extracacta "Sabal Extract WS 1473 in Benign Prostatic Hyperplasia" by Redecker & Bahnhofstrasse
 - d. Urologe "A Combination of Sabal and Urtica Extracts vs. Finasteride in BPH (Stage I to II acc. to Alken: A Comparison of Therapeutic Efficacy in a One Year Double Blind Study"
 - e. Uro "Efficacy of Saw Palmetto Fruit Special Extract WS 1473 in Patients with Alken Stage I-II Benign Prostatic Hyperplasia - Open Mulitcentre Study" by Ziegler & Holscher

98P-0169

Janet Woodcock, M.D. May 25, 1999 Page Two

- Information on Ginkgo Biloba (four papers)
 - a. JAMA, October 22/29, 1997 "A Placebo Controlled, Double-blind, Randomized Trial on an Extract of Ginkgo Biloba for Dementia"
 - b. "Proof of Efficacy of the Ginkgo Biloba Special Extract EGb 761 in Outpatients Suffering From Mild to Moderate Primary Degenerative Dementia of the Alzheimer Type or Multi-Infarct Dementia
 - c. Human Psychopharmacology "A Double Blind Placebocontrolled Trial of Tanakan in the Treatment of Idiopathic Cognitive Impairment in the Elderly"
 - d. American Journal of Therapeutics "Central Nervous System Effects of Ginkgo Biloba, A Plant Extract"

Again, what we are asking for is OTC labeling for those drugs which cause ADRs. I am enclosing a copy of the American Pharmaceutical Association's (APhA) Herbal Chart for Health Care Professionals by June H. McDermott, M.S. Pharm. MBA and Peter Curtis, M.D. from the School of Pharmacy and Family Medicine, University of North Carolina at Chapel Hill with the ADRs on these two specific products. Please note that four major drugs being highly used inhibit platelet aggregation and increased fibrinolytic activity or decrease platelet adhesiveness. Also, please note the number of drugs which should not be taken while pregnant because of the variable effects on INR. These charts were put in the APhA monthly newsletter a year ago.

Perhaps we can prevail on Edward J. Tapper, M.D., V.P., Medical and Clinical R & D, Warner-Lambert Company or Art Ullene, M.D., who make an entire line of nutritional supplements, to put at least the pregnancy warnings on some of their products.

We welcome any suggestions you have as head of FDA's Center for Drug Evaluation and Research. Have you done a recent education and awareness campaign to consumers? If not, is this doable or possible so at least consumers can be made aware of the possible problems.

Please look over the enclosed and get back to me. Thank you for your assistance.

Sincerely

Frederick S. Mayer, R.Ph., M.P.H., President

Enclosures

Warner-Lambert Company 4914 Lambert Place Dublin, VA 24084



Dear Healthcare Professional:

Thank you for responding to our recent introduction of standardized herbal extracts from Warner-Lambert.

As you requested, we have enclosed reprints of key clinical studies on Ginkgo biloba extract EGb 761® and a liposterolic Saw Palmetto extract. You will also receive a separate mailing with information pamphlets to help introduce these extracts to your patients.

Healthcare professionals are being asked more and more frequently by their patients about herbal supplements, so we very much understand and appreciate your desire to learn more about these products. We trust that you will find these enclosed studies to be informative. We also hope that they will help you make informed decisions about integrating these herbal supplements into your practice.

If you have questions or comments, please call Warner-Lambert toll free at 1-800-524-2854.

Sincerely,

Edward J. Tapper, M.D.

V.P., Medical and Clinical R&D

Edward Joppen, MO

Warner-Lambert Company

encs.



101 Lucas Valley Road, Suite 210 • San Rafael, California 94903 Tel: (415) 479-8628 • Fax: (415) 479-8608 • e-mail: ppsi@aol.com

May 25, 1999

Edward J. Tapper, M.D. Vice President, Medical & Clinical R & D Warner-Lambert Company 4914 Lambert Place Dublin, VA 24084

Dear Dr. Tapper:

Many, many thanks for sending along the four research papers on Ginkgo Biloba and the five papers on Saw Palmetto which we have sent on to Janet Woodcock, M.D., FDA. Please send me another set of the above for our records.

PPSI, a 501 C (3) non-profit public health, consumer interest organization would like to see how we can partner with Warner-Lambert on educating health care professionals regarding some of the adverse drug reactions (ADRs) and drug interactions which are associated with some of these nutritional products. We realize that under FDAMA that no labeling is required for these products, but I think it would be prudent for Warner-Lambert, one of the major pharmaceutical companies in the United States, to help educate professionals and consumers on some of these ADRs.

We would welcome any suggestions or thoughts you have on how consumers, patients and health care professionals can be educated and what Warner-Lambert is doing in this field.

I am especially cognizant of the paper entitled "Central Nervous System Effects of Ginkgo Biloba, a Plant Extract" in which in the summary the researchers state "it was established that the electro-physiological effects of EGb in CNS are similar to those of well known cognitive activators such as 'nootropics' as well as tactrine, the only marketed 'antidementia' drug currently available in the United States". If it has the same biological activity as the prescription drug, Tactrine, shouldn't FDA consider this as a drug and not a nutritional supplement? Shouldn't we be getting this type of information out to consumers, patients and health care professionals?

Again, thank you for going the first step in educating health care professionals who request information with some quality studies which we have not previously received from other companies or drug manufacturers of alternative medicines. We look forward to hearing from you and working together on this important issue.

Sincerely,

Frederick S. Mayer, R.Ph., M.P.H., President



Food and Drug Administration Rockville MD 20857

SEP 1 8 1998

Frederick S. Mayer
President
Pharmacists Planning Service, Inc.
101 Lucas Valley Road
Suite 210
San Rafael, California 94903

Re: Docket No. 98P-0169/CP1

Dear Mr. Mayer:

I am writing to inform you that the Food and Drug Administration has not yet resolved the issues raised in your citizen petition submitted on March 16, 1998. Your petition requests that the Agency institute standards for the labeling of botanicals, homeopathics, nutritionals, and natural products that would be similar to the labeling requirements for over-the-counter drugs.

FDA has been unable to reach a decision on your petition because it raises complex issues requiring extensive review and analysis by Agency officials. This interim response is provided in accordance with FDA regulations on citizen petitions (21 CFR 10.30(e)(2)). We will respond to your petition as soon as we have reached a decision on your request.

Sincerely yours,

Janet Woodcock, M.D.

Director

Center for Drug Evaluation and Research



101 Lucas Valley Road, Suite 210 • San Rafael, California 94903 Tel: (415) 479-8628 • Fax: (415) 479-8608 • e-mail: ppsi@aol.com

May 25, 1999

Janet B. McDonald, Ph.D., RD US Public Health Service 1431 Harbor Bay Parkway Alameda, CA 94502 -7070

Dear Janet:

Many, many thanks for the phone call. Yes, I plan to attend the FDA hearing scheduled for July 20th, 1999 from 9:00 a.m. - 5:00 p.m. in Oakland. Please send me registration information. I would like to testify at this hearing on drug interactions and adverse drug effects (ADEs) on nutritionals, alternative medicine and herbs.

Will there be room for the Gray Panthers or other folks who wish to testify?

I have written the enclosed letter to Janet Woodcock, M.D., Director, Center for Evaluation and Research, FDA, regarding our March 16, 1998 Citizen's Petition filed with the FDA for the labeling of botanicals, homeopathics, nutritionals and natural products which would be similar to the labeling requirement for over-the-counter (OTC) drugs.


Please send me the particulars of the upcoming hearing. Many, many thanks for your assistance in putting together the FDA Town Hall Meeting in Oakland on May 12, 1999. We have arranged for some of our concerns and a group meeting with Richard Baldwin on Monday, August 9, 1999. We will discuss some of our prescription drug concerns including the alternative drug labeling issues.

Sincerely,

Frederick S. Mayer, R.Ph., M.P.H. President

Enclosure

cc:	Larry Sasich, Public Citizen	202	E00 7706
CC.		202	588-7796
	Richard Baldwin, FDA	510	637-3976
	Janet Woodcock, M.D.		
	Joanne Ikeda, UCBerkeley	510	642-0535
	Joe Cranston, R.Ph., Ph.D., AMA	312	464-4184
	Lucinda Maine, R.Ph., Ph.D., APhA	202	783-2351



Frederick S. Mayer Pharm B., M.P.H. President

101 Lucas Valley Road, Suite 210 San Rafael, California 94903 Tel: (415) 479-8628 Fax: (415) 479-8608

E-Mail: ppsi@aol.com

.



101 Lucas Valley Road, Suite 210 • San Rafael, California 94903 Tel: (415) 479-8628 • Fax: (415) 479-8608 • e-mail: ppsi@aol.com

M. Wood Sand Market Brook and May

Dear Colleague:

Many, many thanks for your recent request for information on PPSI's public health programs.

PPSI is a non-profit organization and the originator of over thirty-five national programs. Due to limited funds we are requesting a \$15.00 charge for each kit ordered.

Please check off appropriate boxes or requests and return with your remittance of \$15.00 for each kit.

Many, many thanks for your interest and request.

Sincerely,

Joseph I. Rotenberg, R.Ph. Vice President, Professional Affairs

Enclosure

	AIDS		Herpes
	Alcohol		Mental Health
	Allergies		Panic
	Alzheimers		Poison Prevention
, 	Arthritis		STDs
	Cholesterol		Skin Cancer
**	Colorectal Cancer		
	Condom Week		Sleep Disorder
	Depression		Stroke Prevention
	Diabetes		Substance Abuse
- 	Fibromyalgia -		Tobacco Dependence
			Women's Health

T. D. & F a m a n n n g 0 S е S







TO THE PARTY OF TH









Some people think you can catch AIDS from a glass.

<u>You can't.</u>







ORDER FORM

Please send me the following posters Check type and indicate quantity

- _FACTS ABOUT STD _BLACK PREGNANT MAN
- CAUCASIAN PREGNANT MAN
- LATINO PREGNANT MAN
- KEEP A RUBBER ON HAND WHAT CAN YOU GET THE CONDOM
- HERPES/THE CONDOM
- CONDOM WHEEL
- AIDS (get facts) _AIDS (glass)
- 1 only \$5.00 2-10 \$4.75 11-50 \$4.50 51 over \$4.25 100 over \$4.00

Enclosed please find my check

for __posters. Make checks payable and mail to:

VD/Family Planning Program 101 LUCAS VALLEY PA

NAME_


ADDRESS _

CITY




THE REST CONTRACTOR OF THE STATE OF T

PPSI PUBLIC HEALTH PROGRAMS










Children Act Fast... So Can Poleone

PROTECT YOUR CHILDREN says Jiminy Cridest
























SEE YOUR PHARMACIST FOR FREE INFORMATION IN QUARTE THE PHARMACIST FOR FREE INFORMATION

CHECK APPROPRIATE BOXES - FREE INFORMATION FOR PPSI MEMBERS.

CHECK APPROPRIATE BOXES - FREE KITS FOR PPSI MEMBERS. ○ Feb. 14-21

← March April May June Sept. Oct. : Nov. Dec.


National Condom Week Poison Prevention/Vision Care VD/Family Planning Arthritis/Emergency Awareness Child Abuse/Cancer in the Sun Cholesterol Drug Abuse/Pediculosis Diabetes/Epilepsy/Smoke-Out Day Colorectal Cancer

on Members \$15./kit SEND TO: PPSI 101 LUMAS VALLEY RY. SAN RAFAELICA 94903

3rd ANNUAL

National Symposium on Overcoming Barriers to Condom Use

June 1, 1999



Pharmacists Planning Service, Inc.
Columbia University School of
Public Health

The Condom Resource Center Advocates for Youth

Hunter College Center on AIDS, Drugs and Community Health The Alan Guttmacher Institute The National Coalition of STS Directors

SPONSORED BY:

New York University School of Education Department of Studies

Planned Stronthood, New York Public How Association of York

Siew York University of Californe at La Engeles: School of Public Her The University of California at Berkeley, School of Public Health

American Social Health Association

Population Services International

The te for Healthcare

Planned a enthood Federation





ommittee

- ne following list includes individuals who are assisting with the selection of speakers at the conference.
- Presented at Past Conferences)
- Malcolm Potts, MD. PhD. Professor. UC Berkeley Sci Public Health
- dy Guttmacher, PhD Director, Masters of Public Health

Programs, NYU
Allan Rosenfield, MD
Dean, Columbia University School of Public Health

- Katherine Stone, MD Division of STD, CDC
- Paul J. Feidhlum, PhD Pamily Health
- International

 Katherine Forcest, MD

 Past Medical Director,
 Planned Parenthood,
- Santa Clara, CA Frederick S. Mayer, RPh, MPH President, PPSI
- Phil Harvey President, DKT
- International Adam Glickman o-Founder,
- Daniel Bao
- The Condom Resource
 - Nick Freudenberg, Phil Director, Hunt College Center on AIDS, Drugs and Community Health
- Suzi Landolphi Safer Sex Educator Hot Sexy and Safer Kent Klindera, MPH Advocates For Youth



PPSI

101 Lucas Valley Road Suite 210-E San Rafael, CA 94903

Focusing on these Key Issues & New Developments

- Trends in attitudes and usage—U.S. and international
- Advertising, media, and social marketing
- New technologies—urethane, elastomer, female condom, chemical barriers
- Technical update
- Budget cuts, managed care, and other political and financial changes affecting
- Special populations men, women, gay/ lesbian/bi-sexual, youth, communities of color, immigrants and refugees
- Condoms, ethics, and the safer sex message
- Innovative programs

Conference Objectives

- Share information on condom efficacy and technical developments
- Examine institutional, social, and individual factors which affect condom use
- Disseminate info in tion on successful domestic and a successful domestic and a successful transfer of the successful transfer of cation, promotion and availcondo abilit
- gies lo improve Rece conde
- Cash of exercen and action Ider
- nen disciplinary forum for ademon-related issues, and inin a wareness of condom use

Who Should Attend:

Community and public agencies involved in STD/HIV services and family planning, health educators, researchers, peer educators, condom companies, physicians, nu and other clinical provid pharmacists, health of agencies in marke any pre

work your public ex, and condom

I muted amount of table available to exflibit to conference participants Exhibitors receive full access to You are invited to create a conference sessions, breakfast," snacks and beverages. For-Profit Companies \$500

Non-Profit Organizations \$300

Program Abst

aol.com) a your condomam or research. ription will be m a booklet distriball conference partici-Please include: the name de program, the time period as operated, principal meet caff, the target audietiveness to btion must fit box using arger, for-

ram Poster

poster presentation (i.e., word, graph, and picture description in a 6 ft. x 4 ft. space) of your local condom-related program.

There will be prizes awarded for the programs judged most innovative and effective.

The purpose of the poster sessions is to share information in a visual manner about programs and research from around the country, and to provide recognition for outstanding programs. Your poster should vividly communicate key elements of your program, including the target audience, the process or methods by which the program or materials were developed, and the results and limitations of the implemented

All poster session applicants must E-mail a one page summary of their poster, postmarked no later than April 19, 1999.

To present a poster, you must register for the conference, be present to put up and take down your poster on the day it is presented, and submit a program description for the abstract book (see "program abstract book" information).

101 Lucas Valley Road, Suite 210 • San Rafael, California 94903 Tel: (415) 479-8628 • Fax: (415) 479-8608 • e-mail: ppsi@aol.com

April 20, 1999

Dear Conference Participant:

Thank you for registering for the 3rd Annual National Symposium on Overcoming Barriers to Condom Use.

This is confirmation for receipt of your registration and an update on the conference. The conference will be held at the *Loeb Student Center* on the Campus of New York University. New York University is located near Broadway and East 4th Street, in Manhattan, not far from Washington Square Park.

For a great place to stay, about ten minutes from the conference site, we recommend the headquarters hotel of the conference, *The Marriott World Trade Center* (212 938-9100). Normally the rooms at the Marriott are \$290 per night, but if you mention you are with Pharmacists Planning Service's Condom Conference they will give you the discount rate of \$170 per night. We have a list of other hotels as well.

We are looking forward to seeing you at the conference. We anticipate a large number of researchers, professors, clinicians, public health workers, manufacturers and students to attend the conference. We appreciate your joining this eclectic group of people with a common mission of preventing STDs, including HIV and unplanned pregnancy.

Enclosed please find a conference brochure to pass on to a colleague who might want to attend.

Thank you again for your interest and participation. If you have any questions, contact us by email at PPSI@aol.com. See you in New York in June!

Sincerely,

David Silberman, MPH Conference Coordinator